Gene Therapy Market Size, Global Industry Growth Analysis 2020, & Forecast 2021-2026 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Gene Therapy Market


The global Gene Therapy market size is projected to reach US$ 5543.16 million by 2026, from US$ 961.78 million in 2020, at a CAGR of 33.9% during 2021-2026. Many other therapies are also under development, which when approved and marketed, may contribute to significant revenue generation and would boost the industry growth. For instance, in 2018, there were 950 molecules in the development that were expected to be as effective treatment options for different indications like cancer, cardiac diseases, inherited blindness, and various other gene related defects.

Gene therapy involves modification of the faulty and missing gene/s and then delivery to the intended target using modified viral particles or other biotechnologically approved methods. This therapy is mostly considered as a one-time treatment; however, in some cases, it requires more than one dose of medication to completely cure the disease. Gene therapy, once considered impossible on a commercial-scale has now become a trend and most of the companies are banking on breakthrough innovations in the field. Many of the smaller companies have been successful in bringing few molecules to the market with the backing of larger companies.

For instance, major companies like Bristol Myers Squibb are acquiring or funding small-scale companies to support the innovation in exchange for royalties. The global industry is currently in a very important phase of development, with some companies launching a few gene therapy products for commercial usage and with some novel molecules up for commercialization by 2020. Companies are betting big on the revenue returns considering significant investments made in the R&D of the molecules. However, the lack of standard regulations for usage and development, high prices of the marketed products, consumer acceptance, and market presence in other countries or regions are hindering the gene therapy market growth.

As an example of expensive treatment, Kymriah, a gene therapy molecule by Novartis AG launched to treat Acute Lymphoblastic Leukemia (ALL) costs around USD 675,000 per dose and was available only in U.S. at the time of launch. This has resulted in revenues much lesser than expected and predicted by the company and other industry experts from medicine and finance. Such bottlenecks can be overcome with joint efforts from government bodies, manufacturers, and payers, in terms of pricing, regulations, reimbursement for treatment costs, and their efficiency in handling the ethical concerns that would arise with gene therapy, especially in the regions of Asia and Middle East.

Market Segmentation, Outlook & Viewpoint: Global Gene Therapy Market

Indication Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

  
Acute Lymphoblastic Leukemia (ALL)
  
Inherited Retinal Disease
  
Large B-Cell Lymphoma
  
ADA-SCID
  
Melanoma (Lesions)
  
Beta-Thalassemia Major/SCD
  
Head & Neck Squamous Cell Carcinoma
  
Peripheral Arterial Disease

Vector Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

  
Lentivirus
  
AAV
  
RetroVirus & Gamma RetroVirus
  
Modified Herpes Simplex Virus
  
Adenovirus
  
Vaccinia Virus
  
Baculovirus (Bacmid)
  
NON-VIRAL Plasmid Vector
  
Injection of Naked DNA
  
Lipofection

Key Players, Recent Developments & Regional Insights: Global Gene Therapy Market

North America is the dominant regional market, in terms of revenue generation, number of molecules approved for clinical usage, and R&D, which consists around 70% of the global gene therapy pipeline. Many of the companies in U.S. are seeking approvals for next phase of clinical trials and molecules that are ready for commercial usage. In 2018 alone, FDA has approved 3 molecules to treat cancer and inherited blindness and by 2020, it is expected that at least 6 molecules would be on a full commercial scale. Europe follows U.S. with 3 molecules approved for clinical usage; however, one molecule for the treatment of cancer is limited to Russia and Ukraine. In the emerging economies, China leads the market by a significant margin by having two approved drugs that can be used for cancer treatment and with significant pipeline volume.

Gene Therapy Market Share Insights

Novartis AG; UniQure N.V.; Spark Therapeutics LLC; Bluebird Bio; Kite Pharmaceuticals; Gilead Sciences, Inc.; and Human Stem Cell Institute are the key market players with approved molecules and have an extensive product pipeline. Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire PLC, Sangamo Biosciences, Dimension Therapeutics, Voyager Therapeutics, Bristol-Myers Squibb, and Chiesi Farmaceutici S.p.A are some of the active companies with investment in gene therapy development. Intense competition, large pipeline volume, need for novel treatment methods, and numerous growth opportunities for the companies are some of the important factors driving the market.

Key Insights Covered: Global Gene Therapy Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Gene Therapy industry.
2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Gene Therapy industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Gene Therapy industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Gene Therapy industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Gene Therapy industry.

Research Methodology: Global Gene Therapy Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other